Former CFO of Cephalon Inc. and Philips Electronics North America will lead worldwide finance activities for growth oriented global oncology company Novocure Ltd., a commercial stage, private oncology ...

Novocure Ltd . (NASDAQ:NVCR), a pioneering oncology medical technology company valued at $3.62 billion, has been making waves in the cancer treatment sector with its innovative Tumor Treating ...

Piper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more ...

Check Out Our Latest Research Report on NVCR NovoCure Trading Down 3.4 % Shares of NASDAQ NVCR opened at $30.06 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned ...

Analyst Price Forecast Suggests 35.97% Upside As of November 21, 2024, the average one-year price target for NovoCure is $27.25/share. The forecasts range from a low of $18.18 to a high of $42.00.

View Our Latest Stock Report on NovoCure NovoCure Stock Performance NASDAQ NVCR opened at $27.96 on Thursday. The company has a market cap of $3.03 billion, a P/E ratio of -19.97 and a beta of 0. ...

Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough.